Ocular Says Phase III Data Show Hydrogel Axitinib Could Reset Wet AMD Treatment

 
• By Joseph Haas
  
IV2007_Ophthalmology_226242628_1200.jpg
Ocular hopes its Phase III data can position Axpaxli for approval in wet AMD • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business